Genital Herpes News and Research

RSS

FDA clears Roche's automated type-specific herpes tests

Roche announced today that it has received clearance from the U.S. Food and Drug Administration for its IgG Antibody to herpes simplex virus types 1 and 2 assays for use on cobas modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.

From Roche Sequencing and Life Science 5 Sep 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

Declining rates of circumcision in US infant males could add billions to health care costs

A team of disease experts and health economists at Johns Hopkins warns that steadily declining rates of U.S. infant male circumcision could add more than $4.4 billion in avoidable health care costs if rates over the next decade drop to levels now seen in Europe.

21 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2).

6 Aug 2012

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

Sexual intercourse is the major mode of HIV transmission. HIV may also be transmitted through sharing of needles or contaminated blood products (although this is rare).

27 Jul 2012

Maternal antiviral suppressive therapy may not be as effective as thought

Maternal antiviral suppressive therapy does not necessarily prevent the development of neonatal herpes simplex virus disease, warn researchers in The Journal of Pediatrics.

9 Jul 2012

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.

4 Jun 2012

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

2 Apr 2012

Common sexually transmitted bacterial infection more than doubles risk of HIV

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, according to a study by researchers at RTI International.

11 Mar 2012

Infection with M. genitalium may double African women's HIV risk

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, reports a study in the March issue of AIDS.

9 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

New NIST clinical SRM can help in accurate CMV detection and treatment

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

12 Jan 2012

Study confirms condom use reduces risk of HIV infection by 78%

The level of HIV-1 in the blood of an HIV-infected partner is the single most important factor influencing risk of sexual transmission to an uninfected partner, according to a multinational study of heterosexual couples in sub-Saharan Africa.

12 Jan 2012

Starpharma receives FDA Special Protocol Assessment for bacterial vaginosis phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

10 Jan 2012

Investigational HSV vaccine shows promise against two genital herpes diseases

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

5 Jan 2012

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Tenofovir gel no more effective than placebo gel in preventing HIV

An independent review of the VOICE study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the Microbicide Trials Network, determined that tenofovir gel was no more effective than placebo gel in preventing HIV.

28 Nov 2011

C21orf91 gene associated with susceptibility to herpes simplex labialis

Investigators have identified a human chromosome containing a specific gene associated with susceptibility to herpes simplex labialis (HSL), the common cold sore.

28 Oct 2011